I agree that this site is using cookies. You can find further informations here.
X
Durecki, D.
30  results:
Search for persons X
?
1

ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS ..:

Amengual, J. E. ; Shyr, Y. ; Durecki, D....
Hematological Oncology.  41 (2023)  S2 - p. 833-834 , 2023
Link: https://doi.org/10.1002/..
 
?
2

Multicenter Phase II Trial of the PARP Inhibitor Olaparib i..:

Fanucci, Kristina ; Pilat, Mary Jo ; Shyr, Derek...
Cancer Research Communications.  3 (2023)  2 - p. 192-201 , 2023
Link: https://doi.org/10.1158/..
 
?
3

Identifying treatment options for BRAFV600 wild-type metast..:

LoRusso, Patricia M. ; Sekulic, Aleksandar ; Sosman, Jeffrey A....
PLOS ONE.  16 (2021)  4 - p. e0248097 , 2021
Link: https://doi.org/10.1371/..
 
?
4

Wpływ inwestycji z dofinansowaniem unijnym na rozwój przest..:

Durecka, Izabela ; Durecki, Tomasz
Acta Universitatis Lodziensis. Folia Geographica Socio-Oeconomica.  , 2015
Link: https://doi.org/10.18778..
 
?
5

NCI10066: a Phase 1/2 study of olaparib in combination with..:

Cecchini, Michael ; Cleary, James M. ; Shyr, Yu...
British Journal of Cancer.  130 (2023)  3 - p. 476-482 , 2023
Link: https://doi.org/10.1038/..
 
?
6

NCI 7977: A Phase I Dose-Escalation Study of Intermittent O..:

Cecchini, Michael ; Walther, Zenta ; Wei, Wei...
Cancer Research Communications.  3 (2023)  6 - p. 1113-1117 , 2023
Link: https://doi.org/10.1158/..
 
?
7

The influence of investment with European Union funding on ..:

Durecka, Izabela ; Durecki, Tomasz
https://czasopisma.uni.lodz.pl/fgsoe/article/view/20903/20507.  , 2015
Link: https://czasopisma.uni.l..
 
?
8

NCI10066: a Phase 1/2 study of olaparib in combination with..:

Cecchini, Michael ; Cleary, James M ; Shyr, Yu...
qt9gm7d6f1.  , 2024
Link: https://escholarship.org..
 
?
9

Identifying treatment options for BRAFV600 wild-type metast..:

Patricia M LoRusso ; Aleksandar Sekulic ; Jeffrey A Sosman...
https://doi.org/10.1371/journal.pone.0248097.  , 2021
Link: https://doi.org/10.1371/..
 
?
10

Neo-antigen analysis of tumors:

Patricia M. LoRusso (10535356) ; Aleksandar Sekulic (3192720) ; Jeffrey A. Sosman (6517850)...
https://figshare.com/articles/dataset/Neo-antigen_analysis_of_tumors_/14382148.  , 2021
Link: https://doi.org/10.1371/..
 
?
11

Clinical trial design (CONSORT flow diagrams):

Patricia M. LoRusso (10535356) ; Aleksandar Sekulic (3192720) ; Jeffrey A. Sosman (6517850)...
https://figshare.com/articles/figure/Clinical_trial_design_CONSORT_flow_diagrams_/14382157.  , 2021
Link: https://doi.org/10.1371/..
 
?
12

Genomic landscape of trial tumors:

Patricia M. LoRusso (10535356) ; Aleksandar Sekulic (3192720) ; Jeffrey A. Sosman (6517850)...
https://figshare.com/articles/figure/Genomic_landscape_of_trial_tumors_/14382166.  , 2021
Link: https://doi.org/10.1371/..
 
?
13

Reverse phase protein array (RPPA) analysis:

Patricia M. LoRusso (10535356) ; Aleksandar Sekulic (3192720) ; Jeffrey A. Sosman (6517850)...
https://figshare.com/articles/dataset/Reverse_phase_protein_array_RPPA_analysis_/14382121.  , 2021
Link: https://doi.org/10.1371/..
 
?
14

Most common adverse events:

Patricia M. LoRusso (10535356) ; Aleksandar Sekulic (3192720) ; Jeffrey A. Sosman (6517850)...
https://figshare.com/articles/dataset/Most_common_adverse_events_/14382112.  , 2021
Link: https://doi.org/10.1371/..
 
?
15

S1 Protocol -:

Patricia M. LoRusso (10535356) ; Aleksandar Sekulic (3192720) ; Jeffrey A. Sosman (6517850)...
https://figshare.com/articles/journal_contribution/S1_Protocol_-/14382151.  , 2021
Link: https://doi.org/10.1371/..
 
1-15